Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07201376
Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically
Sponsor: Dartmouth-Hitchcock Medical Center
View on ClinicalTrials.gov
Summary
The primary objective of this study is the evaluation of the efficacy of the tissue oxygen imager based on PpIX DF in differentiating benign skin growth from non-melanoma skin cancer (NMSC).
Official title: Tissue Oxygen Imager
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
125
Start Date
2025-11-14
Completion Date
2027-11
Last Updated
2026-02-06
Healthy Volunteers
Yes
Interventions
DRUG
Ameluz 10% Topical Gel
One-time topical application of 10% Ameluz gel for up to 1 hour
DEVICE
Protoporphyrin IX
Tissue oxygen imaging using protoporphyrin IX (PIX), a non-significant risk device.
Locations (1)
Dartmouth Hitchcock
Lebanon, New Hampshire, United States